Sanofi India Limited (SIL) has announced its financial results for the quarter ended June 30, 2025, revealing a mixed performance with challenges in sales but improvements in profitability.

Net Sales Decline

The company reported a 9.00% decline in net sales on a comparable basis of continuing business for the quarter. This decrease in sales highlights the challenges faced by the pharmaceutical sector in the current market environment.

Operating Profit Growth

Despite the decline in net sales, Sanofi India demonstrated resilience in its operations. For the year-to-date period ended June 2025, the company achieved a 6.00% increase in operating profit. This improvement is attributed to the company's focused approach to cost optimization and enhanced operational efficiencies.

Domestic Market Performance

In the domestic market, Sanofi India saw success with its diabetes treatment portfolio:

• The launch of Soliqua®, a premium diabetes treatment for the premix segment, continues to gain momentum.
• Toujeo®, another diabetes medication, maintained strong performance with high single-digit growth.

Strategic Partnerships

Sanofi India's strategic partnerships in the Cardiovascular (CV) and Central Nervous System (CNS) segments have established a solid foundation. These partnerships have met expectations for market reach expansion and business acceleration.

Export Challenges

The company's export sales were negatively impacted by two factors:

1. Non-recurring Consumer Healthcare (CHC) product sales from 2024
2. The planned discontinuation of the Zentiva portfolio

Management Commentary

Rachid Ayari, Whole Time Director and Chief Financial Officer of Sanofi India, commented on the results:

"During this transformative year for our company, our insulin portfolio has demonstrated robust growth, led by Toujeo® and the successful introduction of Soliqua®. Our strategic partnerships have effectively expanded our reach to healthcare professionals in both CV and CNS therapeutic areas, meeting our planned objectives. Moving forward, we remain committed to enhancing operational efficiency while broadening access to both our established products and innovative therapies across India."

Conclusion

Sanofi India continues to focus on its transformation strategy through targeted market initiatives, operational excellence, and innovation advancement in India. The company's efforts to optimize costs and enhance operational efficiencies have yielded positive results in terms of operating profit growth, despite the challenges in net sales.

As Sanofi India navigates through this transformative period, it aims to leverage its strong diabetes portfolio and strategic partnerships to drive growth and expand its market presence in key therapeutic areas.

Sanofi , a prominent player in the pharmaceutical industry, has released its financial results for the second quarter, revealing a mixed performance amid changing market dynamics. The company also announced significant leadership changes and a new strategic partnership in its latest corporate update.

Financial Performance

Sanofi reported a revenue from operations of ₹4,063.00 million for Q2, marking a decrease from ₹5,359.00 million in Q1 and ₹4,635.00 million in Q2 of the previous year. The company's net profit for the quarter stood at ₹695.00 million, down from ₹1,195.00 million in the previous quarter and ₹1,034.00 million in the same quarter last year.

For a comprehensive view of the company's financial performance, here's a breakdown of key metrics:

The half-year results show a total revenue of ₹9,422.00 million and a net profit of ₹1,890.00 million.

Leadership Changes

Sanofi announced the retirement of Ms. Renee Amonkar from her position as Whole-time Director and Site Director - Goa, effective August 11.

Simultaneously, the company announced the appointment of Mr. Mahadev Gawade as an Additional and Whole-time Director for a three-year term, also effective from August 11. Mr. Gawade, who will serve as the new Site Director - Goa, brings over 20 years of experience in logistics and manufacturing within the pharmaceutical industry. His appointment is subject to shareholder approval.

Strategic Partnership

Sanofi has entered into a promotion and distribution agreement with Emcure Pharmaceuticals Limited for its Oral Anti-diabetic (OAD) business products. This partnership is expected to enhance the reach and distribution of Sanofi's diabetic care products in the Indian market.

Outlook

While Sanofi faces challenges reflected in its quarterly performance, the company's strategic moves, including leadership changes and the new partnership with Emcure Pharmaceuticals, signal its commitment to adapting to market conditions and pursuing growth opportunities. The impact of these changes on the company's performance will be closely watched by investors and industry analysts in the coming quarters.

Sanofi continues to operate in a single business segment, focusing on its core pharmaceutical business. The company's ability to navigate the evolving healthcare landscape and capitalize on its strengths will be crucial in shaping its future performance and market position.